-
Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation
•
Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech Co., Ltd., and AccurEdit Therapeutics will be housed at its Bayer Co.Lab Shanghai. This move aims to leverage Bayer’s global innovation and cooperation network, connecting global pharmaceutical industry resources to boost cell and gene therapy…
-
Epigenic Therapeutics Receives Approval for EPI-003 Clinical Study in New Zealand
•
Shanghai-based Epigenic Therapeutics, a biotechnology company specializing in the development of novel gene modulation therapies, has announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) and The Health and Disability Ethics Committees (HDEC) to conduct a clinical study for its investigational drug,…
-
Epigenic Therapeutics Secures $32 Million in Series A Funding for Gene Modulation Therapy
•
Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has successfully raised USD 32 million in a Series A financing round. The round was co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital. The funds will be utilized to…
